- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 237/24
Total number of patents in this class: 268
10-year publication summary
|
21
|
15
|
16
|
18
|
23
|
24
|
17
|
28
|
21
|
15
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
23 |
| Theravance Biopharma R&D IP, LLC | 458 |
14 |
| Syngenta Crop Protection AG | 6054 |
12 |
| Celgene Quanticel Research, Inc. | 163 |
10 |
| Novartis AG | 10849 |
8 |
| Nihon Nohyaku Co., Ltd. | 327 |
8 |
| Bayer AG | 3330 |
7 |
| Bayer Cropscience AG | 2035 |
5 |
| FMC Corporation | 844 |
5 |
| Boehringer Ingelheim International GmbH | 4650 |
4 |
| The Scripps Research Institute | 1346 |
4 |
| Lieber Institute, Inc. | 40 |
4 |
| F. Hoffmann-La Roche AG | 7925 |
3 |
| Janssen Pharmaceutica N.V. | 3392 |
3 |
| Syngenta Participations AG | 1903 |
3 |
| Cytokinetics, Inc. | 277 |
3 |
| St. Jude Children's Research Hospital, Inc. | 217 |
3 |
| Vanderbilt University | 1901 |
3 |
| Inflazome Limited | 85 |
3 |
| Xcovery Holdings, Inc. | 22 |
3 |
| Other owners | 140 |